

Summary of Risk Management Plan for
Enrylaze[®]
(CRISANTASPASE (RECOMBINANT))
Marketing Authorization Number 69073

Document date : 01/Jun/2024

Based on EU RMP version 2.0

Document version : 1.0

Jazz Pharmaceuticals Switzerland GmbH

Grafenauweg 8, 6300 Zug, Schweiz

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken to further investigate and follow the risks as well as to prevent or minimise them.

The RMP summary of Enrylaze is a concise document and does not claim to be exhaustive. As the RMP is an international document, the summary might differ from the “Arzneimittelinformation / Information sur le médicament” approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization.

Please note that the reference document which is valid and relevant for the effective and safe use of Enrylaze in Switzerland is the “Arzneimittelinformation/ Information sur le médicament” (see www.swissmedic.ch) approved and authorized by Swissmedic.

Jazz Pharmaceuticals Switzerland GMBH is fully responsible for the accuracy and correctness of the content of the published summary RMP of Enrylaze.

PART VI SUMMARY OF RISK MANAGEMENT PLAN FOR ENRYLAZE (CRISANTASPASE (RECOMBINANT))

This is a summary of the risk management plan (RMP) for Enrylaze. The RMP details important risks of Enrylaze, how these risks can be minimised, and how more information will be obtained about Enrylaze's risks and uncertainties (missing information).

Enrylaze's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Enrylaze should be used.

This summary of the RMP for Enrylaze should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Enrylaze's RMP.

I The Medicine and What it is Used For

Enrylaze is authorised as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adults and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to *E. coli*-derived asparaginase. It contains crisantaspase (recombinant) as the active substance and it is given intramuscularly or intravenously.

Further information about the evaluation of Enrylaze's benefits can be found in Enrylaze's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage <https://www.ema.europa.eu/en/medicines/human/EPAR/enrylaze>.

II Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks

Important risks of Enrylaze, together with measures to minimise such risks and the proposed studies for learning more about Enrylaze's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of Important Risks and Missing Information

Important risks of Enrylaze are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Enrylaze. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of Important Risks

The safety information in the Product Information is aligned to the reference medicinal product.

II.C Post-Authorisation Development Plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Enrylaze.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Enrylaze.

Signature Page for JZP458 Enrylaze - Summary of RMP V.2.0 Published
VV-PVG-003442

Approval Task - Approval of Document Signing Verdict/Reason: I Approved This Document	Mark Daniels Pharmacovigilance 03-Jun-2024 10:39:09 GMT+0000
--	--

Approval Task - Approval of Document Signing Verdict/Reason: I Approved This Document	Ilaria Grisoni QPPV/Deputy 03-Jun-2024 11:18:11 GMT+0000
--	--

Approval Task - Approval of Document Signing Verdict/Reason: I Approved This Document	Badrish Patel Pharmacovigilance 03-Jun-2024 11:55:05 GMT+0000
--	---

Signature Page for JZP458 Enrylaze - Summary of RMP V.2.0 Published
VV-PVG-003442